EUVIMEDEUVIMED entdecken
Crossref

A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomes

Wentao Yang iD, Rongji Mu iD, Zhangsheng Yu iD

Biometrics · 09.04.2026 · 82 (2)

DOI: 10.1093/biomtc/ujag096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, online erschienen am 19.06.2026. Verfasst von Wentao Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Mathematical Sciences, Shanghai Jiao Tong University, Shanghai 200240, PR China. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Research Design. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Jiao Tong University, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Delayed outcomes, such as late-onset toxicity and efficacy, present substantial challenges in dose optimization during Bayesian phase I/II platform trials for drug therapies across multiple indications. To address these challenges and ensure timely, reliable dose selection, we propose an enhanced Bayesian phase I/II platform design with data augmentation method accounting for delayed outcomes (BPDD). The BPDD design uses an iterative augmentation process to predict unobserved outcomes, combining observed and imputed data to refine dose-toxicity and dose-efficacy estimates, which not only supports optimal decision-making but also significantly reduces the time required for clinical trials. By borrowing information across indications through hierarchical modeling, our approach improves the accuracy of parameter estimates and facilitates efficient risk-benefit trade-off analyses. At each interim analysis, these updated estimates guide decisions on dose escalation, de-escalation, and optimal biological dose identification for each indication. Simulation studies demonstrate the robustness and flexibility of our approach in managing delayed outcomes, highlighting its accuracy and time efficiency in dose optimization. This framework has the potential to enhance clinical trial efficiency, accelerate drug development, and improve decision-making in multi-indication platform trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicClinical Trials, Phase II as TopicResearch DesignBayes TheoremHumansComputer SimulationDose-Response Relationship, DrugModels, Statistical

Stichwörter der Autor:innen

Bayesian adaptive designdata augmentation methoddose optimizationplatform trial

Autor:innen und Institutionen

  • School of Mathematical Sciences, Shanghai Jiao Tong University, Shanghai 200240, PR China.
  • Institute of Clinical Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, PR China.

ORCID-Profile: Wentao Yang, Rongji Mu, Zhangsheng Yu

Förderung

  • National Natural Science Foundation of China
  • Shanghai Jiao Tong University
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Yang, W., Mu, R., & Yu, Z. (2026). A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomes. Biometrics, 82(2). https://doi.org/10.1093/biomtc/ujag096

Vancouver

Yang W, Mu R, Yu Z. A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomes. Biometrics. 2026;82(2). doi:10.1093/biomtc/ujag096

BibTeX
@article{Yang2026,
  author = {Yang, Wentao and Mu, Rongji and Yu, Zhangsheng},
  title = {A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomes},
  journal = {Biometrics},
  year = {2026},
  volume = {82},
  number = {2},
  doi = {10.1093/biomtc/ujag096}
}
Kostenlos starten →